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1. Introduction
Concern regarding halitosis is estimated to be the third most frequent reason for people to seek
dental care, following tooth decay and periodontal disease [1]. Compared with tooth decay
and periodontal disease, there are a diverse number of causes of halitosis. Table 1 shows a
commonly used classification of halitosis [2 – 4]. Obvious bad breath is termed genuine
halitosis, which is classified as physiological and pathological halitosis. Pathological halitosis
is further sub-classified into halitosis as a result of oral and extra-oral causes. Physiological
and oral pathological halitosis occur in the oral cavity, and comprise 85% or more of genuine
halitosis [5, 6]. Physiological halitosis generally occurs at the time of waking or starving, and
likely results from increased microbial metabolic activity that is aggravated by a physiological
reduction in salivary flow, oral cleaning, and inadequate mouth cleaning before sleep or after
eating [4]. Clinical causes of oral pathological halitosis include poor oral hygiene, tongue
debris, periodontitis, inadequately fitted restorations, deep caries, endodontic lesions,
ulceration, and low salivary flow [7 – 11]. The most common malodorous compounds that
cause oral-derived malodor are volatile sulfur compounds (VSCs) such as hydrogen sulfide
(H2S) and methyl mercaptan (CH3SH), which are associated with microbial amino acid
metabolism [12, 13]. Halitosis derived from extra-oral causes is less common, but causes
include respiratory disorders, gastrointestinal diseases, metabolic disorders, and drugs [2 –
4]. The smell of gases that have accumulated in organs during respiratory disorders and
gastrointestinal diseases can be emitted directly from the oral cavity and nose. Malodorous
components caused by some metabolic disorders and drugs circulate in the bloodstream and
are exhaled in the breath after alveolar gas exchange. Components of extra-oral malodor
include those due to disease, such as acetone in uncontrolled diabetes and trimethylamine in
trimethylaminuria (“fish odor syndrome” [14]). Dimethyl sulfide (CH3SCH3), a VSC, is the
main contributor to extra-oral or blood-borne halitosis via an as-yet-unknown metabolic
disorder [15]. Some patients that complain of halitosis do not have bad breath. Although
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pseudo-halitosis is not diagnosed as a psychiatric disorder, some patients with this condition
exhibit neurotic tendencies more frequently than do patients with genuine halitosis [6].
Halitophobia is characterized by a patient’s persistent belief that he or she has halitosis, despite
reassurance, treatment, and counseling. Many patients with halitophobia have slight bad
breath at their first visit to a dental clinic. However, the presence of a mental condition together
with bad breath has been suggested in these individuals.
Classification (treatment needs) Description
Genuine halitosis Obvious malodor, and of an intensity beyond the socially acceptable level is
perceived.
Physiological halitosis (TN-1) Malodor arises through putrefactive processes within the oral cavity. No
specific diseases or pathological conditions that could cause halitosis are
found.
Pathological halitosis
Oral (TN-1 and TN-2) Halitosis caused by a disease or a pathological condition that causesmalfunction of the oral tissues.
Extra-oral (TN-1 and TN-3) Malodor that originates from a respiratory system, gastrointestinal tract,metabolic disorders, or drugs.
Pseudo-halitosis (TN-1 and TN-4) No objective evidence of malodor, although the patient thinks they have it.
Halitophobia (TN-1 and TN-5) The patient persists in believing they have halitosis despite reassurance,
treatment, and counseling.
Table 1. Classification of halitosis [2-4].
All patients that complain of halitosis should receive an explanation of halitosis and instruc‐
tions for oral hygiene (TN-1; Table 2) [16]. Further professional instruction, education, and
reassurance are necessary for patients with pseudo-halitosis (TN-4). Professional cleaning and
treatment of oral diseases are performed in patients with oral pathological halitosis (TN-2),
and treatment and control of the systemic causative disease by a physician or medical specialist
is provided for patients with extra-oral pathological halitosis (TN-3). Medical treatment by a
psychological specialist is required for the treatment of halitophobia, regardless of the presence
of bad breath (TN-5).
Category Treatment regimen
TN-1 Explanation of halitosis and instructions for oral hygiene.
TN-2 Oral prophylaxis, professional cleaning, and treatment for oral diseases, particularly periodontal
diseases.
TN-3 Referral to a physician or medial specialist.
TN-4 Explanation of the examination data, further professional instructions, education, and reassurance.
TN-5 Referral to a clinical psychologist, psychiatrist, or other psychological specialist.
Table 2. Treatment needs (TN) for halitosis [2, 16] useful for clinical dentists.
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Most genuine halitosis occurs in the oral cavity, and is known as oral-derived malodor. As
mentioned above, VSCs are produced during the metabolism of the sulfur-containing amino
acids cysteine and methionine by bacteria [12, 13]. Gram-negative anaerobes in the oral cavity
are important producers of VSCs. Periodontopathic bacteria isolated from subgingival
plaques, such as Porphyromonas gingivalis, Prevotella intermedia, Tannerella forsythia, and
Treponema denticola, generate significant amounts of H2S and CH3SH [17]. The genera Veillo‐
nella, Actinomyces and Prevotella are H2S-producing normal inhabitants of the tongue coating
[18]. Solobacterium moorei is present in the tongue dorsa of subjects with halitosis, specifically
[19]. A recent investigation of the bacterial composition of saliva reported that high proportions
of the genera Neisseria, Fusobacterium, Porphyromonas, and SR1 were present in patients with
high H2S and low CH3SH, whereas high proportions of the genera Prevotella, Veillonella,
Atopobium, Megasphaera, and Selenomonas were detected in patients with high CH3SH and low
H2S [20]. The human oral cavity contains more than 500 bacterial species that interact both
with each other and host tissues, suggesting that various bacteria might play roles in malodor
production. The treatment strategy for oral-derived malodor is the acquisition of a normal
microbiota, as well as reducing the numbers of bacteria. The prevention and treatment of oral
malodor involve primarily the removal of any causative clinical conditions, predominantly
via oral hygiene instructions and the treatment of oral diseases. Persistent malodor usually
originates from the posterior dorsum of the tongue and/or oral/dental diseases, including
periodontal diseases. Tongue cleaning and the treatment of periodontal diseases are effective
for improving oral malodor [21, 22]. In addition, many products such as mouthwash, denti‐
frice, gel, gum, oil, tablets, and lozenges can play supporting roles in controlling oral malodor.
Such products improve oral malodor by reducing bacterial load and/or nutrient availability,
exerting anti-inflammatory effects, and converting VSCs into non-volatile substances. The
active ingredients used for controlling oral malodor can be separated into chemical agents and
naturally derived compounds. Examples of chemical agents include chlorhexidine, cetylpyr‐
idinium chloride, zinc chloride, triclosan, stannous fluoride, hydrogen peroxide, chlorine
dioxide, and sodium fluoride. Naturally derived compounds can be sub-classified into natural
botanical extracts (e.g., actinidine, hinokitiol, eucalyptus-extract, green tea, magnolia bark
extract, and pericarp extract of garcinia mangostana L), salivary components (lactoferrin and
lactoperoxidase), and probiotic bacteria (Lactobacillus salivarius, Lactobacillus reuteri, Weissella
cibaria, and Streptococcus salivarius). In this chapter, these various approaches to the prevention
and treatment of oral malodor are summarized.
2. Chemical agents
Chlorhexidine (CHX), cetylpyridinium chloride (CPC), triclosan, zinc ions (Zn2+), and chlorine
dioxide (ClO2) are all known to inhibit oral malodor [23, 24]. In many cases, these active
ingredients have been used in mouthwashes and dentifrices, both individually and in
combinations. CHX digluconate has been used most frequently to treat oral cavities as an active
ingredient in mouthwash that is designed to reduce dental plaque and oral bacteria. CHX is
used in mouthwashes at 0.12% or 0.2%, and a previous study revealed that these two concen‐
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trations of CHX had an identical effect on gingival inflammation [25]. Young et al. [26]
evaluated the inhibitory effects of CHX, CPC, and Zn2+on VSC production. Data revealed that
0.2% CHX and 1% Zn2+exhibited excellent inhibitory effects, and had similar effects on VSC
production; however, the two agents had different anti-VSC kinetics. Briefly, 0.2% CHX had
a sustained inhibitory effect, whereas Zn2+had an immediate effect. In contrast, 0.2% CPC had
only a mild inhibitory effect on VSC production. These ingredients are found in commercial
mouthwashes, often in combination. Roldán et al. [27] compared five commercial mouth‐
washes in a randomized, double-blind, crossover trial: 0.12% CHX alone, 0.12% CHX plus 5%
alcohol, 0.12% CHX plus 0.05% CPC, 0.12% CHX plus sodium fluoride, and a combination of
0.05% CHX, 0.05% CPC, and 0.14% Zn2+. In this study, the combination of 0.12% CHX plus
0.05% CPC resulted in the greatest reduction in oral bacterial numbers. In contrast, the
combination of 0.05% CHX, 0.05% CPC and 0.14% Zn2+provided the most immediate reduction
in VSC levels. Zn2+can be effective in reducing the activity of VSCs directly, in addition to its
antimicrobial effect [28]. It has been reported that a combination of Zn2+and CHX or CPC
inhibited VSC formation synergistically [29]. ClO2 and chlorite anion (ClO2-) also oxidize VSCs
directly into non-malodorous products, which consumes the amino acids that act as precursors
to VSCs [30, 31]. A randomized double-blind crossover placebo-controlled clinical trial found
that mouth rinsing with ClO2 effectively reduced morning malodor for 4 h in healthy volun‐
teers [32]. Triclosan is a broad-spectrum antibacterial agent that blocks lipid synthesis in
susceptible bacteria [33]. A double-blind, crossover, randomized study comparing the VSC-
reducing effects of mouthwashes on morning bad breath in healthy subjects reported that VSC
formation was inhibited by, in descending order, mouthwashes containing 0.12% CHX
gluconate, 0.03% triclosan, essential oils, and 0.05% CPC [34].
However, there are concerns regarding the potential side effects of these chemical agents. The
use of 0.2% CHX results in an unpleasant bitter taste, perturbs taste, causes desquamative
lesions and soreness of the oral mucosa, and yellow/brown staining of the teeth and dorsum
of the tongue [35]. Hypersensitivity to CHX is rare, but several immediate-type allergies such
as contact urticarial, occupational asthma, and anaphylactic shock have been reported [36,
37]. In Japan, based on these reports, the concentration of CHX used near a wound is limited
to 0.05%, which is lower than its effective concentration. Recently, the possibility that triclosan
is hazardous to human health has been suggested. Several studies reported that triclosan might
contribute to bacterial resistance to antibiotics, or interfere with endocrine functions in rats [38,
39]. The US Food and Drug Administration (FDA) named triclosan in the National Toxicology
Program (NTP) for toxicological evaluation.
3. Naturally derived compounds (Table 3)
3.1. Natural botanical extracts
Due to the increase in health consciousness, many flavors and natural botanical extracts have
been added to foods and medicine to reduce oral malodor. In addition, the effects of natural
botanical extracts on oral malodor have been evaluated in randomized controlled trials.
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Study Conditions for the 
assessment (the period that 
avoided oral activities, 
mouth cleaning, etc.) 
Study population 
(Age) 
Study design Follow-up time Active 
ingredient 
Study group Sample size Pretreatment Vehicle Frequency 
(washout period) 
Malodor 
assessment 
Results 
Natural botanical extracts            
Tanaka et al [41]. 4:30–6:30 pm (at least 4 h) Volunteers with 
gingivitis or mild 
periodontitis  
(20–50 years) 
Double-blind, 
randomized, 
placebo-controlled 
parallel trial 
14 weeks Eucalyptus 
extract 
High-
concentration 
(0.6%), low-
concentration 
(0.4%), and 
placebo 
32, 32, and 
33, 
respectively 
Full-mouth 
supragingival 
scaling 
Chewing gum Two tablets for 5 
min, five times 
daily for 12 weeks 
OLT score, 
VSCs by GC 
The OLT score decreased significantly 
at 4, 8, 12 and 14 weeks in the 0.4%- 
and 0.6%-eucalyptus extract groups 
but not in the placebo group. The 
group-time interactions revealed 
significant reductions in the OLT score 
and VSCs in both experimental groups 
compared with the placebo group.  
Rassameemasmaung 
et al [47]. 
7:00–8:30 am (at least 2 h) Gingivitis patients 
 (18–55 years) 
Double-blind, 
placebo-controlled 
parallel trial 
4 weeks Green tea 
extract 
Green tea and 
placebo 
Both n = 30 None Mouthwash Twice daily for 4 
weeks 
VSCs by 
Halimeter 
The VSC levels decreased significantly 
at 30 min, 3 h, and day 28 in the green 
tea group. On day 28 there was a 
significant difference between the 
green tea and placebo group.  
Rassameemasmaung 
et al [49]. 
8:00 am (at least 2 h) Gingivitis patients 
 (17–37 years) 
Double-blind, 
randomized, 
placebo-controlled 
parallel trial 
8 weeks The pericarp 
extract of 
Garcinia 
mangostana L 
Garcinia and 
placebo 
Both n = 30 1) None 
2) Scaling 
Mouthwash Twice daily for 2 
weeks (4 weeks) 
VSCs by 
Halimeter 
1) The VSC levels decreased 
significantly in the Garcinia group 
compared with baseline and the 
placebo group. 
2) The VSC levels in the Garcinia 
group was reduced significantly 
compared with the placebo group, but 
not with baseline.  
Iha et al [52]. At the same time of day (at 
least 5 h) 
Patients with oral 
malodor (33–71 years) 
Randomized, 
open-label, 
parallel trial 
4 weeks Hinokitiol Hinokitiol and 
0.01% CPC 
Both n = 9 None Gel Three times daily, 
for 4 weeks 
OLT score, H2S 
and CH3SH 
levels using GC 
The OLT score, and the levels of H2S 
and CH3SH were reduced significantly 
in the hinokitiol group, whereas the 
OLT score was improved significantly 
in the 0.01% CPC group. 
Nohno et al [54]. Morning (at least 4 h) Male volunteers  
(24–54 years) 
Double-blind, 
randomized, 
placebo-controlled 
crossover trial 
4 weeks Actidinine Actidinine and 
placebo 
Both n = 14 None Tablet Three times daily, 
for a week  
(2 weeks) 
VSCs by Oral 
Chroma 
The VSC levels were reduced 
significantly in both the test and 
placebo groups after just taking a 
tablet. The VSC level was reduced 
significantly in the test group, but not 
in the placebo group, after use for 1 
week.  
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 Study Conditions for the 
assessment (the period that 
avoided oral activities, 
mouth cleaning, etc.) 
Study population 
(Age) 
Study design Follow-up time Active 
ingredient 
Study group Sample size Pretreatment Vehicle Frequency 
(washout period) 
Malodor 
assessment 
Results 
Salivary components            
Shin et al [57]. Morning (from the 
midnight before) 
Volunteers with oral 
malodor (26–54 years) 
Double-blind, 
randomized, 
placebo-controlled 
crossover trial 
1 week Lactoferrin and 
Lactoperoxidase
Lactoferrin and 
Lactoperoxidase, 
and placebo 
Both n = 15 None Tablet Twice at a 1-h 
interval in the 
morning (1 week) 
H2S, CH3SH, 
and total VSCs 
by GC 
The CH3SH level was significantly 
lower in the test group compared with 
the placebo group 10 min after the first 
ingestion. The median concentration 
of CH3SH in the test group was below 
the olfactory threshold from 10 min 
until 2 h, whereas the level in the 
placebo group remained above the 
threshold during the experimental 
period.   
Probiotic bacteria            
Kang et al [58]. 7:00–8:00 am (from the 
evening before) 
Student volunteers  
(20–30 years) 
Open label 
crossover trial 
1 day Weissella cibaria 
CMU 
W. cibaria CMU, 
Lactobacillus casei, 
Weissella confuse, 
and distilled water
46, 10, 10, 
and 46, 
respectively 
None Solution 15 mL for 2 min, 
twice daily 
H2S and CH3SH 
using Oral 
Chroma 
Rinsing of the mouth with solutions 
containing W. cibaria CMU twice a day 
significantly reduced H2S and CH3SH 
the next morning; L. casei, W. confuse, 
and distilled water had no effect. 
Burton et al [63]. Morning (from awakening) Subjects with oral 
malodor (18–69 years) 
Open label 
parallel trial 
1 week Sterptococcus 
salivarius K12 
 S. salivarius K12 
and placebo 
13 and 10 Mechanical and 
chemical oral 
cleansing 
treatment 
Lozenge Day 1: at 2-h 
intervals over 8 h. 
Afterwards: twice 
daily for a week 
VSCs by 
Halimeter 
The VSC levels 1 week after treatment 
initiation was reduced significantly in 
the test group compared with the 
placebo group. 
Keller et al [70].  Morning (from the evening 
before) 
Young adult volunteers 
(19–25 years) 
Double-blind, 
randomized, 
placebo-controlled 
crossover trial 
7 weeks Lactobacillus 
reuteri DSM 
17938 and 
ATCC PTA 
5289 
L. reuteri and 
placebo 
Both n = 25 None Chewing gum Twice daily for 2 
weeks (3 weeks) 
OLT, VSCs by 
Halimeter 
The OLT score was significantly lower 
in the probiotic group compared with 
the placebo group. The VSC levels 
were not significantly different 
between groups. 
Suzuki et al [76]. At the same time of day (at 
least 5 h) 
Patients with oral 
malodor (22–67 years) 
Double-blind, 
randomized 
crossover trial 
6 weeks Lactobacillus 
salivarius WB21 
L. salivarius WB21 
and placabo 
Both n = 23 None Tablet Three daily for 2 
weeks (2 weeks) 
OLT, VSCs by 
GC 
The OLT score was reduced 
significantly in both the probiotic and 
placebo periods. VSC levels were 
reduced significantly in the probiotic 
period but not in the placebo period. 
 
OLT, organoleptic test; VSCs, volatile sulfur compounds; GC, gas chromatography; H
2 S, hydrogen sulfide; CH
3 SH, methyl
mercaptan.
Table 3. Clinical trials to evaluate the effects of naturally derived compounds on reducing oral malodor.
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Eucalyptus extract is one of the four active ingredients of Listerine® mouthwash (Pfizer Inc.,
Morris Plains, NJ, USA), which was created in 1879 and was formulated originally as a surgical
antiseptic. It has antibacterial activity against several periodontopathic bacteria including P.
gingivalis and P. intermedia, which produce VSCs [40]. The effect on oral malodor of chewing
gum containing eucalyptus extract was evaluated in a double-blind randomized trial over a
12-week period [41]. Relative to baseline, organoleptic test (OLT) scores decreased significantly
at 4, 8, 12, and 14 weeks in the 0.4%-and 0.6%-eucalyptus extract groups, but not in the placebo
group. In addition, the group-time interactions revealed significant reductions in OLT scores,
VSC levels, and tongue-coating scores in both eucalyptus concentration groups compared with
the placebo group.
The catechins present in green tea have in vitro bactericidal activity against the odor-producing
periodontal bacteria P. gingivalis and Prevotella spp. [42], inhibit the adherence of P. gingivalis
to oral epithelial cells [43], and reduce periodontal breakdown by inhibiting the collagenase
and cysteine proteinase activity of P. gingivalis [44, 45]. It was reported that green tea powder
reduced VSC concentrations in mouth air immediately after administration [46]. A double-
blind placebo-controlled clinical trial found that rinsing the mouth with green tea containing
mouthwash twice per day significantly reduced VSC levels at 30 min, 3 h, and day 28,
compared with baseline [47]. There was a significant difference between the green tea group
and the placebo group at day 28 [47].
Pericarp extracts of Garcinia mangostana, which is commonly known as the mangosteen tree,
exert antimicrobial activity against the oral bacteria Streptococcus mutans and P. gingivalis, and
exhibit anti-inflammatory effects [48]. The use of mouthwash containing pericarp extracts of
G. mangostana twice daily for 2 weeks reduced VSC levels significantly compared with baseline
and the placebo group [49]. Furthermore, rinsing with mouthwash containing G. mangostana
L for 2 weeks after scaling and polishing reduced VSC level significantly compared with
placebo, whereas there was no significant difference between baseline and day 15 [49].
Hinokitiol (β-thujaplicin), a component of essential oils isolated from Cupressaceae, shows
antibacterial activity against various bacteria, including periodontopathic bacteria and fungi
[50, 51], and has been used as a therapeutic agent against periodontal disease and oral Candida
infections. An open-label, randomized, controlled trial was performed in patients with genuine
halitosis to evaluate the effects of mouth cleaning using hinokitiol-containing gels on oral
malodor [52]. Mouth cleaning, including the teeth, gingiva, and tongue, was performed three
times per day for 4 weeks. Organoleptic test (OLT) scores, levels of H2S and CH3SH, the
frequency of bleeding on probing, mean probing pocket depths, and plaque indices were
improved significantly in the group treated using the hinokitiol-containing gel. In contrast,
only OLT scores improved significantly in the control group treated using 0.01% CPC-
containing control gel.
Actidinine is a cysteine protease derived from the kiwi fruit. Tongue coating is understood to
be an important factor in oral malodor and is composed of proteins [22, 53]. The effect of a
tablet containing actidinine on oral malodor was evaluated in a double-blind, randomized
crossover trial [54]. The subjects sucked the tablets three times per day for 1 week. VSC levels
and tongue-coating ratios decreased significantly on the first day in both the test and placebo
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groups immediately after taking a tablet. VSC levels were significantly lower after 7 days only
in the test group. There was no significant reduction in tongue-coating ratios in either group
after 7 days of use.
3.2. Salivary components
Saliva contains a variety of antimicrobial proteins including lactoferrin, peroxidase, lysozyme,
and secretory immunoglobulin A. Lactoferrin is an iron-binding glycoprotein that chelates two
ferric ions per molecule, and decreases bacterial growth, biofilm development, iron overload,
reaction oxygen formation, and inflammatory processes [55]. Salivary peroxidase, in the
presence of H2O2 and SCN-, can reversibly inhibit bacterial enzyme and transport systems by
oxidizing the sulfhydryl groups of proteins [56]. A reduction in salivary flow might inhibit
antimicrobial defense systems in saliva. A relationship between low salivary flow and the
generation of H2S and CH3SH in mouth air has been reported previously [8].
The effect of a tablet containing lactoferrin and lactoperoxidase purified from bovine milk on
oral malodor was evaluated in a randomized, double-blind, crossover, placebo-controlled
clinical trial [57]. According to that study, CH3SH levels were significantly lower in the test
group compared with the placebo group 10 min after taking a tablet. The median CH3SH
concentration in the test group was below the olfactory threshold between 10 min and 2 h,
whereas the level in the placebo group was above the threshold throughout the experimental
period.
3.3. Probiotic bacteria
The use of probiotics as preventative and therapeutic products for oral healthcare is a novel
antimicrobial approach that has been proposed as an alternative to chemotherapeutics.
Probiotics are defined as “live microorganisms that confer a health benefit on the host when
administered in adequate amounts” by the World Health Organization and the Food and
Agriculture Organization of the United States (http://www.who.int/foodsafety/fs_manage‐
ment/en/probiotic_guidelines.pdf). Probiotics have been used traditionally to treat diseases
related to the gastrointestinal tract. Recently, the use of such probiotics to improve oral health
has attracted increasing attention, although this field is still in its infancy. Nevertheless, there
are several reports related to the use of probiotics to ameliorate oral malodor.
Kang et al. isolated three peroxide-generating lactobacilli, identified as W. cibaria, from the
saliva of kindergarten children aged 4–7 years who had little supragingival plaque and no oral
disease, including dental caries [58]. These isolates co-aggregated with F. nucleatum, inhibited
VSC production by F. nucleatum, and prevented proliferation by F. nucleatum in vitro. Subse‐
quently, the effect of W. cibaria CMU on morning odor was evaluated in a clinical trial of healthy
volunteers. Rinsing the mouth using solutions containing W. cibaria CMU twice per day
reduced production of H2S and CH3SH the next morning significantly. Conversely, use of
solutions containing distilled water, Lactobacillus casei, and Weissella confusa had no effect.
Streptococcus salivarius K12 has been used to prevent the pharyngitis and tonsillitis induced by
Streptococcus pyogenes. S. salivarius was selected as an oral probiotic because it is an early
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colonizer of oral surfaces and is the predominant member of tongue microbiota numerically
in ‘healthy’ individuals [19, 59]. S. salivarius K12 produces two bacteriocins: salivaricin A and
salivaricin B [60, 61]. It exerts inhibitory activities against oral malodor-related oral bacteria,
such as Atopobium parvulum, Eubacterium sulci, and S. moorei, to varying extents [62]. According
to an additional in vitro study, inhibitory effects were observed against Streptococcus angino‐
sus, Eubacterium saburreum, and Peptostreptococcus micros, but not P. gingivalis and P. interme‐
dia [63]. This report described the results of a preliminary clinical trial that administered
lozenges containing either S. salivarius K12 or placebo. The subjects undertook a 3-day regimen
of CHX mouth rinsing followed by the use of lozenges at specific intervals. The VSC levels 1
week after the initiation of treatment were reduced significantly in the S. salivarius K12 group
compared with the placebo group. The salivary bacterial composition was examined using
PCR-denaturing gradient gel electrophoresis, and data revealed that it changed in most
subjects following K12 treatment, albeit to differing extents.
Lactobacillus reuteri is a member of the indigenous oral microbiota in humans, and it exerts
antibacterial properties by converting glycerol into reuterin, a broad-spectrum antimicrobial
substance [64]. Products that contain L. reuteri have been marketed for the prevention and
treatment of gingivitis and periodontal disease [65-67]. However, data are conflicting regard‐
ing the potential of L. reuteri for caries management, as some studies reported useful effects
whereas other did not [68, 69]. The effect of chewing gum containing two strains of probiotic
lactobacilli (L. reuteri DSM 17938 and L. reuteri ATCC PTA 5289) on oral malodor was evaluated
in a randomized double-blinded placebo-controlled crossover trial [70]. The study populations
were healthy volunteers, and the study design included two intervention periods of 2 weeks
with a 3-week washout period. The organoleptic scores were significantly lower in the
probiotic group compared with the placebo group. However, there were no differences in VSC
levels between the two groups, either before or after rinsing with L-cysteine. The researchers
hypothesized that the probiotic gum might have affected bacteria that produce malodorous
compounds other than VSCs.
Lactobacillus salivarius WB21 is an acid-tolerant lactobacillus derived from L. salivarius WB1004
[71], and is a potentially effective probiotic against Helicobacter pylori. Oral consumption of
tablets containing L. salivarius WB21 was reported to improve periodontal conditions in
healthy volunteer smokers and reduce the numbers of the periodontopathic bacterium T.
forsythia in subgingival plaque [72, 73]. A double-blind, randomized, placebo-controlled
clinical trial using oils containing L. salivarius WB21 in patients with periodontal disease
reported reduced bleeding on probing compared with the placebo group after 2 weeks [74].
We performed an open-label pilot study previously to evaluate whether oral administration
of a tablet containing L. salivarius WB21 altered oral malodor or clinical conditions in patients
complaining of oral malodor [75]. The organoleptic scores and concentrations of H2S and
CH3SH were reduced in patients without periodontitis after 2 weeks of treatment, and the
organoleptic scores and bleeding on probing were decreased in patients with periodontitis
after 4 weeks. Subsequently, we performed a 14-day, double-blind, randomized, placebo-
controlled crossover trial using tablets containing L. salivarius WB21 or placebo taken orally
by patients with oral malodor [76]. The organoleptic scores were decreased significantly in
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both the probiotic and placebo periods compared with the baseline scores, and there was no
difference between periods. Compared with the values at baseline, the concentrations of total
VSCs decreased significantly in the probiotic period but not in the placebo period, and
significant differences were observed between the two periods. In addition, the mean probing
pocket depth decreased significantly in the probiotic period compared with the placebo period.
Quantitative analysis of the bacteria in saliva found significantly lower levels of ubiquitous
bacteria and F. nucleatum during the probiotic period.
4. Conclusions
Chemical agents have been used widely to prevent and treat oral malodor. However, long-
term use of some antiseptic agents such as CHX might result in complications such as staining
of teeth and the development of microbial resistance. In addition, recent studies have raised
concern regarding the potentially harmful effects of triclosan on the human body. These
phenomena and consumers’ increasing health consciousness have led to the development of
alternative antimicrobial approaches, including herbs, natural botanical extracts, salivary
components, and probiotics. Diverse natural products have been marketed as effective for
preventing and treating oral malodor, and an increasingly diverse range of strategies for oral
malodor is available. However, few studies have demonstrated effectiveness of new products
against oral malodor clinically. Furthermore, most studies evaluated the short-term effects of
products on oral malodor, either immediately or only a few weeks after taking the products.
However, the products used for preventing and treating oral malodor, including mouthwash,
toothpaste, tablets, and lozenges, are generally used for the long term. Therefore, the long-
term effects of agents on oral malodor, as well as their safety and side effects, should be
evaluated in randomized controlled trials.
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